Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vir Biotechnology Inc (NQ: VIR )

9.260 +1.770 (+23.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
Vir Biotechnology Gets Price Targets Cuts By Analysts After Q4 Results
Vir Biotechnology, Inc. (NASDAQ: VIR) reported worse-than-expected Q4 results. Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s... 
Via Benzinga
The Top 7 Growth Stocks in Biotech
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Where Vir Biotechnology Stands With Analysts
Via Benzinga
Vir Biotechnology's Earnings Outlook
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Analyst Expectations for Vir Biotechnology's Future
Via Benzinga
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose... 
Via Benzinga
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Final draft guidance based on cost effectiveness evaluation of sotrovimab 
From Vir Biotechnology, Inc.
Via GlobeNewswire
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.  
Via Benzinga
Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,... 
Via Benzinga
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
From Vir Biotechnology, Inc.
Via GlobeNewswire
Insiders Selling Meta Platforms And 3 Other Stocks
The Nasdaq dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
Via Benzinga
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
From Vir Biotechnology, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.